$ASPI
ASP Isotopes Inc.

2023 Q2 Form 10-Q Financial Statement

#000147793223003751 Filed on May 19, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $4.095M $3.517M $1.377M
YoY Change 230.28% 517.1%
% of Gross Profit
Research & Development $252.9K $207.3K $94.44K
YoY Change -43.36% -29.25%
% of Gross Profit
Depreciation & Amortization $167.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $4.348M $3.725M $1.472M
YoY Change 157.83% 334.0%
Operating Profit -$4.348M -$3.725M
YoY Change 425.09% 334.0%
Interest Expense $1.100K -$540.00 $1.480K
YoY Change -24.14%
% of Operating Profit
Other Income/Expense, Net $61.20K $109.7K $166.2K
YoY Change 7656.4% 16403.16%
Pretax Income -$4.286M -$3.615M -$1.304M
YoY Change 154.42% 320.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.286M -$3.615M -$1.304M
YoY Change 154.42% 321.54%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.12
Diluted Earnings Per Share -$0.14 -$0.12 -$0.06
COMMON SHARES
Basic Shares Outstanding 37.39M shares 37.39M shares 34.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.626M $5.082M $2.389M
YoY Change 28.89%
Cash & Equivalents $3.626M $5.082M $2.389M
Short-Term Investments
Other Short-Term Assets $404.4K $688.3K $913.0K
YoY Change -45.62%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $4.031M $5.771M $3.302M
YoY Change 13.31% 2.51%
LONG-TERM ASSETS
Property, Plant & Equipment $7.735M $8.006M $8.201M
YoY Change 19.55% 174.43%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $342.7K $133.6K $139.6K
YoY Change
Total Long-Term Assets $8.720M $8.836M $9.194M
YoY Change 34.78% 134.46%
TOTAL ASSETS
Total Short-Term Assets $4.031M $5.771M $3.302M
Total Long-Term Assets $8.720M $8.836M $9.194M
Total Assets $12.75M $14.61M $12.50M
YoY Change 27.16% 74.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $670.1K $1.287M $1.355M
YoY Change -23.8% 2170.32%
Accrued Expenses $807.6K $408.6K $361.2K
YoY Change 22.09% 749.99%
Deferred Revenue
YoY Change
Short-Term Debt $33.85K $33.85K $33.85K
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.949M $1.996M $1.936M
YoY Change 7.34% 538.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $648.2K $698.0K $742.4K
YoY Change -19.26%
Total Long-Term Liabilities $648.2K $698.0K $742.4K
YoY Change -19.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.949M $1.996M $1.936M
Total Long-Term Liabilities $648.2K $698.0K $742.4K
Total Liabilities $2.597M $2.694M $2.679M
YoY Change -0.82% 133.96%
SHAREHOLDERS EQUITY
Retained Earnings -$15.45M -$11.17M -$7.553M
YoY Change 189.62%
Common Stock $373.9K $373.9K $359.1K
YoY Change 73.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.15M $11.91M $9.817M
YoY Change
Total Liabilities & Shareholders Equity $12.75M $14.61M $12.50M
YoY Change 27.16% 74.95%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$4.286M -$3.615M -$1.304M
YoY Change 154.42% 321.54%
Depreciation, Depletion And Amortization $167.00 $0.00
YoY Change
Cash From Operating Activities -$1.257M -$1.445M -$862.0K
YoY Change -9.15% 401.82%
INVESTING ACTIVITIES
Capital Expenditures $146.6K $362.1K $902.5K
YoY Change -91.54% -59.72%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$146.6K -$362.1K -$902.5K
YoY Change -91.54% -59.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $4.494M 3.790M
YoY Change -100.0% 101.24%
NET CHANGE
Cash From Operating Activities -1.257M -$1.445M -862.0K
Cash From Investing Activities -146.6K -$362.1K -902.5K
Cash From Financing Activities 0.000 $4.494M 3.790M
Net Change In Cash -1.403M $2.687M 2.026M
YoY Change 428.41% 156.82%
FREE CASH FLOW
Cash From Operating Activities -$1.257M -$1.445M -$862.0K
Capital Expenditures $146.6K $362.1K $902.5K
Free Cash Flow -$1.403M -$1.807M -$1.765M
YoY Change -54.96% 52.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3517490 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
565202 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
3724824 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3724824 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-858253 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3615078 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-857588 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001921865
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35907127 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37385684 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Other Commitment
OtherCommitment
7233000 usd
CY2022Q4 aspi Accounts Payable
AccountsPayable
400000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q1 aspi Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
0 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41555
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ASP Isotopes Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2618235
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
433 Plaza Real
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 275
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
CY2023Q1 dei City Area Code
CityAreaCode
561
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
709-3034
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ASPI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37385684 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
858253 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-935 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2022Q1 aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
0 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
396 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
665 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109746 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
665 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-3615078 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-857588 usd
CY2023Q1 aspi Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.12
CY2022Q1 aspi Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.03
CY2023Q1 aspi Weighted Average Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted
29141525 shares
CY2022Q1 aspi Weighted Average Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted
26404834 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3615078 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-857588 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1003853 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-229257 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4618931 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1086845 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5997664 usd
CY2022Q1 aspi Issuance Of Common Stock Net Of Issuance Costs Of285024 Amount
IssuanceOfCommonStockNetOfIssuanceCostsOf285024Amount
2090186 usd
CY2022Q1 aspi Issuance Of Restricted Common Stock Upon Exercise Of Warrants Amount
IssuanceOfRestrictedCommonStockUponExerciseOfWarrantsAmount
0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20803 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-229257 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-857588 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7021808 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9817461 usd
CY2023Q1 aspi Issuance Of Common Stock And Warrants Net Of Issuance Costs Of506390 Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsOf506390Amount
4493610 usd
CY2023Q1 aspi Cancellation Of Common Stock Received In Exchange For Issuance Of Convertible Preferred Stock In Subsidiary Amount
CancellationOfCommonStockReceivedInExchangeForIssuanceOfConvertiblePreferredStockInSubsidiaryAmount
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
75570 usd
CY2023Q1 aspi Issuance Of Restricted Shares Amount
IssuanceOfRestrictedSharesAmount
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2144099 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1003853 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3615078 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11911809 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2144099 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20803 usd
CY2023Q1 aspi Fair Value Of Common Stock To Consultants
FairValueOfCommonStockToConsultants
266200 usd
CY2022Q1 aspi Fair Value Of Common Stock To Consultants
FairValueOfCommonStockToConsultants
0 usd
CY2023Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-110285 usd
CY2022Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
17034 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
19057 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
0 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-58348 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
203959 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
16372 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-34 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-388443 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
310655 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
47404 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
189000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9821 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
72102 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1444965 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-287947 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
362056 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
898918 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-362056 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-898918 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2375210 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
506390 usd
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
129200 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
13046 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4493610 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2232964 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2686589 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1046099 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6561 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-229241 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2389140 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953721 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5082290 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3770579 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
0 usd
CY2022Q1 us-gaap Stock Issued1
StockIssued1
95808 usd
CY2023Q1 aspi Unpaid Financing Fees
UnpaidFinancingFees
0 usd
CY2022Q1 aspi Unpaid Financing Fees
UnpaidFinancingFees
60817 usd
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
337158 usd
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
0 usd
CY2023Q1 aspi Settlement Of Share Liability
SettlementOfShareLiability
75570 usd
CY2022Q1 aspi Settlement Of Share Liability
SettlementOfShareLiability
0 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
3615078 usd
CY2022Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
857588 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
5082290 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the three months ended March 31, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Our foreign subsidiaries held cash of approximately $144,000 and $38,000 as of March 31, 2023 and December 31, 2022, respectively, which is included in cash on the consolidated balance sheets.  Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S.  If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.</p>
CY2023Q1 aspi Federal Deposit Insurance
FederalDepositInsurance
250000 usd
CY2023Q1 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
144000 usd
CY2022Q4 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
38000 usd
CY2023Q1 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
220800 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
116200 usd
CY2022 aspi Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
174782 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-150527 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
140455 usd
CY2023Q1 aspi Hgu
hgu
-75570 usd
CY2023Q1 aspi Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
266200 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-110285 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
220800 usd
CY2023Q1 aspi Lease Liability Current
LeaseLiabilityCurrent
46551 usd
CY2023Q1 aspi Lease Liability Noncurrent
LeaseLiabilityNoncurrent
697950 usd
CY2023Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
8005633 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
8200595 usd
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
100000 usd
CY2022Q1 aspi Royalty Percentage On Sale Of Products
RoyaltyPercentageOnSaleOfProducts
0.10 pure
CY2023Q1 aspi Accounts Payable
AccountsPayable
400000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
33854 usd
CY2023Q1 us-gaap Loss On Contracts
LossOnContracts
6800000 usd
CY2023Q1 us-gaap Other Commitment
OtherCommitment
7233000 usd
CY2023Q1 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
6050000 usd
CY2021Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.075 pure
CY2021Q4 aspi Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
952521 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
952521 usd
CY2023Q1 aspi Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
696367 usd
CY2023Q1 aspi Operating Lease Lease Liability Current
OperatingLeaseLeaseLiabilityCurrent
46551 usd
CY2023Q1 aspi Operating Lease Lease Liability Noncurrent
OperatingLeaseLeaseLiabilityNoncurrent
697950 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
31160 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
36258 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
23948 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
25922 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q1 aspi Remaining Lease Term Years
RemainingLeaseTermYears
P7Y9M
CY2022Q1 aspi Remaining Lease Term Years
RemainingLeaseTermYears
P8Y9M
CY2023Q1 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2022Q1 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
75198 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
106500 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
114488 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
123074 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
132305 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
459483 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1011048 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
266547 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
744501 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37385684 shares
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1559780 shares
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.00
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3119560 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
255965 usd
CY2022 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
62391 shares
CY2022Q4 aspi Fair Value Of Shares Issue
FairValueOfSharesIssue
124782 usd
CY2022Q4 us-gaap Stock Issued During Period Shares Dividend Reinvestment Plan
StockIssuedDuringPeriodSharesDividendReinvestmentPlan
1250000 shares
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.00
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3800000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
3000000 shares
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
2500 shares
CY2023Q1 aspi Exchange Of Common Shares Into Convertible Preferred Stock
ExchangeOfCommonSharesIntoConvertiblePreferredStock
3000000 shares
CY2023Q1 aspi Cash Director Fees
CashDirectorFees
45000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
3164557 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
506390 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.603 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0344 pure
CY2023Q1 aspi Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P5Y6M
CY2023Q1 aspi Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6000000 shares
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2901000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
CY2023Q1 aspi Weighted Average Remaining Contractual Term In Years Beginning
WeightedAverageRemainingContractualTermInYearsBeginning
P9Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
199500 usd
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2901000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
CY2023Q1 aspi Weighted Average Remaining Contractual Term In Years Ending
WeightedAverageRemainingContractualTermInYearsEnding
P9Y1M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
90600 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
602221 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.79
CY2023Q1 aspi Weighted Average Remaining Contractual Term In Years Exercisable
WeightedAverageRemainingContractualTermInYearsExercisable
P9Y1M6D
CY2023Q1 aspi Aggregate Intrinsic Value Exercisable
AggregateIntrinsicValueExercisable
42783 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2901000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.91
CY2023Q1 aspi Weighted Average Remaining Contractual Term In Years Vested Or Expected To Vest
WeightedAverageRemainingContractualTermInYearsVestedOrExpectedToVest
P9Y1M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
90600 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
50000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.00
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.16
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.75
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1256750 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.80
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
537500 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.70
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7719250 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.67
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2144099 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20803 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3615078 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-857588 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
29141525 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
26404834 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2901000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
450000 shares
CY2023Q1 aspi Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
3386076 shares
CY2023Q1 aspi Restricted Stock
RestrictedStock
7719250 shares
CY2023Q1 aspi Shares Of Common Stock Equivalents
SharesOfCommonStockEquivalents
14006326 shares
CY2022Q1 aspi Shares Of Common Stock Equivalents
SharesOfCommonStockEquivalents
450000 shares

Files In Submission

Name View Source Status
0001477932-23-003751-index-headers.html Edgar Link pending
0001477932-23-003751-index.html Edgar Link pending
0001477932-23-003751.txt Edgar Link pending
0001477932-23-003751-xbrl.zip Edgar Link pending
aspi-20230331.xsd Edgar Link pending
aspi_10q.htm Edgar Link pending
aspi_ex311.htm Edgar Link pending
aspi_ex312.htm Edgar Link pending
aspi_ex321.htm Edgar Link pending
aspi_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
aspi-20230331_cal.xml Edgar Link unprocessable
aspi-20230331_pre.xml Edgar Link unprocessable
aspi-20230331_lab.xml Edgar Link unprocessable
aspi-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aspi_10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending